FLT3 and acute myeloid leukemia: Furthermore, notably, our findings also demonstrate that co-treatment with SNDX-5613 and adavosertib exerts superior preclinical in vivo efficacy compared to each drug alone against AML expressing mtNPM1 and FLT3 mutations.